Viome Life Sciences, a leading company in preventative health and longevity, has successfully closed an oversubscribed Series C funding round, raising $86.5 million. The company focuses on understanding the molecular activity of the body, enabling personalized health insights and recommendations for its users. This new funding will be instrumental in accelerating the company’s mission to prevent and reverse chronic diseases and extend human lifespan.
Key Highlights
- Viome Life Sciences leverages advanced metatranscriptomic sequencing technology to analyze the function of microbial, mitochondrial, and human RNA in the body.
- The company’s platform provides actionable insights, allowing users to understand their body’s needs better and make informed decisions about their health.
- With the new funding, Viome aims to expand its reach, further its research, and enhance its platform capabilities.
Source: PR Newswire
Notable Quotes
- “Our mission is to make illness optional. We believe that our health care system is broken because it focuses on managing symptoms and not addressing the root cause.” – Naveen Jain, Founder and CEO of Viome Life Sciences
- “With this new funding, we are one step closer to transforming how society approaches health and wellness, moving from a sick care system to a true health care system.”
SoH's Take
- Viome Life Sciences’ focus on metatranscriptomic sequencing technology positions the company at the forefront of personalized health care. By understanding the body’s molecular activity, Viome offers a unique approach to preventative health, which is gaining traction in the health care industry.
- The oversubscribed Series C funding round indicates strong investor confidence in Viome’s vision and technology. As the health care paradigm shifts from treatment to prevention, companies like Viome are poised to play a pivotal role in this transformation.
